Recent advancements in research has led to the development of effective therapeutics to combat neurodegenerative diseases, giving patients a renewed sense of hope there will ultimately be a more effective treatment.

CEO Lisa Deschamps and her team at AviadoBio are among those conducting research in the space, but they’re doing things a little differently. They’ve been given a unique drug designation by the FDA to develop a treatment for frontotemporal dementia (FTD), a crippling neurodegenerative disorder that affects neuron production in people under 65. It may be a “bold and courageous” undertaking, but the benefits could affect future generations to come.

Join us as we take a look at the motivation behind the work AviadoBio is doing, what makes their therapy unique, and Lisa’s vision for their future.

Show Notes 

• AviadoBio 
• S4, E01: Project ALS: Fueled by Love 
• S3, E01: A Synergistic Approach to Treating Huntington's Disease 
• Charles River | Neuroscience 
• Charles River | Gene Therapy for Neurological Disorders 
• Charles River| GEne Therapy Services